Aditx Therapeutics(ADTX) - 2025 Q2 - Quarterly Report

Cautionary Note Regarding Forward-Looking Statements and Industry Data This section outlines forward-looking statements, emphasizing that actual results may differ due to known and unknown risks - The company has generated no significant revenue from commercial sales to date and future profitability is uncertain[9] - The company's financial situation creates substantial doubt about its ability to continue as a going concern, requiring additional funding which may not be available or may be dilutive[9][42] - Significant risks include regulatory approval process challenges, potential delays in clinical studies, and the inability to successfully commercialize product candidates[9] - Dilution risk exists due to significant issuance of convertible preferred stock, warrants, and potential future equity sales (e.g., $150M common stock purchase agreement, $35M ATM offering)[10][14] PART I FINANCIAL INFORMATION This part presents Aditxt's unaudited condensed consolidated financial statements, covering balance sheets, operations, equity, and cash flows Item 1. Condensed Consolidated Financial Statements (Unaudited) This section provides core unaudited condensed consolidated financial statements, offering a snapshot of the company's financial health Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 | Metric | June 30, 2025 | December 31, 2024 | Change | | :--------------------------------- | :-------------- | :---------------- | :----- | | Cash | $323,679 | $833,031 | $(509,352) | | Total Current Assets | $433,655 | $1,999,841 | $(1,566,186) | | Notes receivable, related party, net of discount | $2,196,826 | $- | $2,196,826 | | Investment in Evofem | $27,542,071 | $27,277,211 | $264,860 | | Total Assets | $32,691,232 | $32,144,390 | $546,842 | | Total Current Liabilities | $20,582,619 | $23,407,123 | $(2,824,504) | | Total Liabilities | $20,696,368 | $23,857,994 | $(3,161,626) | | Total Stockholders' Equity | $11,994,864 | $(86,604) | $12,081,468 | Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 | Metric | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | | :--------------------------------- | :----------------------------- | :----------------------------- | :----------------------------- | :----------------------------- | | Sales | $1,004 | $44,276 | $2,022 | $123,956 | | Cost of goods sold | $1,005 | $23,134 | $1,739 | $88,933 | | Gross profit (loss) | $(1) | $21,142 | $283 | $35,023 | | Total operating expenses | $6,152,394 | $5,997,123 | $11,760,793 | $17,546,650 | | Net loss from operations | $(6,152,395) | $(5,975,981) | $(11,760,510) | $(17,511,627) | | Total other expense | $(1,243,263) | $(1,647,898) | $(1,587,613) | $(4,980,946) | | Net loss before income taxes | $(7,395,658) | $(7,623,879) | $(13,348,123) | $(22,492,573) | | Net loss attributable to Aditxt, Inc. & Subsidiaries | $(7,256,808) | $(7,549,619) | $(12,967,117) | $(22,279,346) | | Net loss per share, basic and diluted | $(3.45) | $(1,047.17) | $(9.22) | $(3,262.64) | | Weighted average number of shares outstanding | 2,101,701 | 7,210 | 1,406,545 | 6,829 | - The decrease in revenue and cost of goods sold is attributed to decreased AditxtScore orders due to reduced COVID testing[246][251] - Net loss per share significantly improved from $(1,047.17) to $(3.45) for the three months ended June 30, 2025, and from $(3,262.64) to $(9.22) for the six months ended June 30, 2025, despite continued operational losses[19] Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 | Metric | December 31, 2024 | June 30, 2025 | Change | | :--------------------------------- | :---------------- | :-------------- | :----- | | Total Stockholders' Equity (Deficit) | $(86,604) | $11,994,864 | $12,081,468 | | Additional Paid-in Capital | $168,792,592 | $194,219,137 | $25,426,545 | | Accumulated Deficit | $(168,094,569) | $(181,061,686) | $(12,967,117) | - Issuance of shares from registered direct offerings and ELOC (Equity Line of Credit) significantly contributed to additional paid-in capital[22] - The company redeemed Series A-1 and Series C-1 Convertible Preferred Stock during the period[22] Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | | :--------------------------------- | :----------------------------- | :----------------------------- | :----- | | Net loss | $(13,348,123) | $(22,492,573) | $9,144,450 | | Net cash used in operating activities | $(14,098,132) | $(8,250,807) | $(5,847,325) | | Net cash provided by investing activities | $(2,425,000) | $(1,000,000) | $(1,425,000) | | Net cash provided by financing activities | $16,013,780 | $9,244,928 | $6,768,852 | | NET DECREASE IN CASH | $(509,352) | $(5,879) | $(503,473) | | CASH AT END OF PERIOD | $323,679 | $91,223 | $232,456 | - Cash used in operating activities significantly increased from $(8.25) million in 2024 to $(14.10) million in 2025[28] - Proceeds from common stock and warrants issued for cash, net of issuance costs, were $24.78 million in 2025, a substantial increase from $3.02 million in 2024[28] Notes to Condensed Consolidated Financial Statements This section provides detailed disclosures on accounting policies, financial instruments, and related party transactions NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS - Aditxt, Inc. operates as an innovation platform focused on discovering, developing, and deploying promising innovations through an ecosystem of research institutions, industry partners, and shareholders[30] - The company effectuated a 1-for-40 reverse stock split on October 2, 2024, and a 1-for-250 reverse stock split on March 14, 2025, to adjust its stock trading basis on Nasdaq[31][32] - In May and August 2024, the company completed private placements and registered direct offerings, raising approximately $4.2 million and $1.2 million gross proceeds, respectively, for working capital and merger obligations[34][36] - The company has a limited operating history and is in the very early stages of generating revenue, facing risks related to the biotechnology regulatory environment, technological advances, clinical trial resources, and competition[37] NOTE 2 – GOING CONCERN ANALYSIS - The company incurred a net loss of $13,348,123 and negative cash flow from operating activities of $14,098,132 for the six months ended June 30, 2025, with a cash balance of $323,679[38] - As of June 30, 2025, the company was subject to the "Baby Shelf Limitation" under Form S-3, restricting its ability to offer and sell securities under its shelf registration statement to one-third of the aggregate market value of non-affiliate equity[39] - The company's financial situation creates substantial doubt about its ability to continue as a going concern, actively pursuing capital raising transactions (equity, debt, private placements, public offerings, related-party loans) to meet existing and longer-term capital needs[41][42][44][45] - Delisting from Nasdaq could adversely affect the value and liquidity of common stock, warrants, and pre-funded warrants, and hinder financing efforts[40] NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial statements are prepared in accordance with U.S. GAAP for interim information, reflecting normal, recurring adjustments[46] - Significant estimates include the value of preferred shares, derivative liability, investment in Evofem preferred stock, and fair value of stock options and warrants[49] | Financial Instrument | Carrying Value (June 30, 2025) | Fair Value Measurement Using Level 2 | | :--------------------------- | :----------------------------- | :----------------------------------- | | Derivative liability | $392 | $392 | | Investment in Evofem warrants | $264,860 | $264,860 | | Total | $265,252 | $265,252 | - Revenue from AditxtScore™ services is recognized upon delivery of the report, following a five-step process for identifying contracts, performance obligations, transaction price, allocation, and recognition[85][93] - The company accounts for stock-based compensation under ASC 718, recognizing expense over the vesting period, and expenses R&D and sales & marketing costs as incurred[94][96][97] - Non-controlling interest represents the cumulative results attributable to non-controlling shareholders in its majority-owned subsidiary, Pearsanta, Inc. (90% owned)[98] NOTE 4 – FIXED ASSETS | Asset Category | Net Value (June 30, 2025) | Net Value (December 31, 2024) | | :--------------------- | :------------------------ | :-------------------------- | | Computers | $1,069 | $4,120 | | Lab Equipment | $1,346,092 | $1,462,751 | | Office Furniture | $32,433 | $35,121 | | Other Fixed Assets | $5,231 | $5,661 | | Leasehold Improvements | $27,451 | $40,121 | | Total Fixed Assets | $1,412,276 | $1,547,774 | - Depreciation expense for the six months ended June 30, 2025, was $135,498, a decrease from $300,129 in the prior year[102] - All lab equipment financing agreements have matured and are in default status as of June 30, 2025, with the company having four to seven payments in arrears on various agreements[104][105][106] NOTE 5 – INTANGIBLE ASSETS | Asset Category | Net Value (June 30, 2025) | Net Value (December 31, 2024) | | :--------------------- | :------------------------ | :-------------------------- | | Proprietary Technology | $- | $- | | Intellectual property | $4,444 | $6,111 | | Total Intangible Assets | $4,444 | $6,111 | - Amortization expense for intangible assets was $1,667 for the six months ended June 30, 2025[107] - The company's proprietary technology is fully amortized over its estimated useful life of three years[107] NOTE 6 – RELATED PARTY TRANSACTIONS - CEO Amro Albanna and Chief Innovation Officer Shahrokh Shabahang provided short-term, unsecured loans to the company in May and June 2025, totaling $493,000, all of which were fully repaid by June 30, 2025[109][110][111] - Aditxt purchased a senior subordinated convertible note from Evofem (a related party) in April 2025 for $1.5 million, with a principal amount of $2,307,692 and warrants to purchase 149,850,150 shares of Evofem common stock[113] - In June 2025, Aditxt purchased another senior subordinated convertible note from Evofem for $925,000, with a principal amount of $1,423,077 and warrants to purchase 92,407,592 shares of Evofem common stock[118] - The Evofem notes accrue interest at 8% per annum (12% upon default) and are convertible into Evofem common stock at $0.0154 per share, subject to a 9.99% beneficial ownership cap[114][119] NOTE 7 – NOTES PAYABLE - The November Loan Agreement ($560,268 principal) and January Loan Agreement ($2,000,336 principal) are both in default status as of June 30, 2025, with 49% interest rates[125][126] - The May 2025 Note, with a principal balance of $1,114,286, is also in default status as of June 30, 2025, bearing 10% interest (20% upon default)[130][132] - A new June Senior Note was issued for $1,000,000 principal, with a purchase price of $800,000 (reflecting a $100,000 original issue discount), bearing 10% interest and maturing September 30, 2025[134] - The company entered into forbearance agreements with preferred stock holders, agreeing to redeem Series A-1 and C-1 Preferred Shares under certain financing conditions[131] NOTE 8 – LEASES - The company's corporate headquarters lease in Mountain View, California, became month-to-month as of September 1, 2024, and payments are current[136] - The Richmond, Virginia, facility lease expires on August 31, 2026, and the company is two months in arrears as of June 30, 2025[137] - A default notice was received in May 2024 for $590,557 related to the Richmond lease, with $431,182 paid, but the company remains two months in arrears[138] | Metric | June 30, 2025 | December 31, 2024 | | :--------------------------------- | :-------------- | :---------------- | | Right of use asset – long term | $886,014 | $1,225,781 | | Operating lease liabilities – short term | $693,613 | $683,352 | | Operating lease liabilities – long term | $113,357 | $436,354 | | Total lease liability | $806,970 | $1,119,706 | NOTE 9 – COMMITMENTS & CONTINGENCIES - Aditxt has an exclusive worldwide license from Loma Linda University (LLU) for ADI™ technology, requiring annual fees, milestone payments (e.g., $100,000 due Sept 30, 2024, $500,000 due Sept 30, 2026), and royalties on net product/service sales[143][144] - The company is in default on several LLU milestone deadlines, including the September 30, 2024 payment and the initiation of first-in-human clinical trials, and intends to obtain extensions[144][145] - Aditxt holds an exclusive worldwide license from Stanford for AditxtScore™ technology, requiring an annual maintenance fee ($60,000 starting 2025) and royalties (4-6% of Net Sales)[146][147][148] - A call option to purchase Evofem securities for $13 million was not exercised by its June 30, 2025, expiration[150] - The Arrangement Agreement with Appili was terminated effective May 31, 2025, resulting in a $1,250,000 termination fee, with $1,000,000 remaining outstanding as of June 30, 2025[155] NOTE 10 – STOCKHOLDERS' EQUITY - Aditxt effectuated a 1-for-250 reverse stock split on March 14, 2025, and its subsidiary Pearsanta underwent a 1-for-60 reverse stock split on the same date[157][158] | Equity Offering | Period | Shares Sold | Average Price per Share | Net Proceeds | | :---------------------- | :--------------------------------- | :---------- | :---------------------- | :------------- | | ATM Offering | Six months ended June 30, 2025 | 2,048,002 | $4.18 | ~$8,560,920 | | ELOC Purchase Agreement | Six months ended June 30, 2025 | 853,959 | $18.99 | ~$16,216,915 | - The company redeemed 268 shares of Series A-1 Convertible Preferred Stock for $308,000 and approximately 6,110 shares of Series C-1 Convertible Preferred Stock for $7,027,070 during the six months ended June 30, 2025[166][167] - Pearsanta acquired patents for DNA adduct detection, issuing 200 shares of Pearsanta Series B Convertible Preferred Stock valued at $10,000[168] - Stock-based compensation expense for warrants was $473,311 for the six months ended June 30, 2025, with no new stock options granted during the period[186][172] NOTE 11 – INCOME TAXES - The company incurred losses since inception and did not provide any income tax provision for the six months ended June 30, 2025[187] - A full valuation allowance has been recorded against net deferred tax assets as of June 30, 2025, due to cumulative losses, indicating uncertainty regarding the realization of these assets[187] NOTE 12 – SEGMENT REPORTING - Aditxt operates in one operating segment, focused on the discovery and development of biopharmaceutical products aimed at the global market[189] - The chief operating decision makers (CEO and CFO) use consolidated net loss, along with non-financial inputs and qualitative information, to evaluate performance, allocate resources, and establish compensation[191] NOTE 13 – SUBSEQUENT EVENTS - From July 1, 2025, through the report date, the company redeemed approximately 275 shares of Series C-1 Convertible Preferred Stock for $316,632 and repaid the June 2025 Promissory Note[193][194] - On August 13, 2025, the CEO and Chief Innovation Officer loaned an additional $95,000 each to the company via unsecured promissory notes[195] | Equity Offering | Period | Shares Sold | Average Price per Share | Net Proceeds | | :---------------------- | :--------------------------------- | :---------- | :---------------------- | :------------- | | ELOC Activity | July 1, 2025 - Report Date | 1,569,021 | $1.01 | ~$1,586,996 | | ATM Activity | July 1, 2025 - Report Date | 230,605 | $1.34 | ~$293,450 | Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management discusses Aditxt's financial condition, operational results, mission, and ongoing challenges, including going concern Overview and Mission - Aditxt's mission is to transform promising innovations into products and services by harnessing the power of large groups of stakeholders[199][200] - The company was incorporated on September 28, 2017, and is headquartered in Mountain View, California[200] - Initial focus was on immune modulation technology (ADI/Adimune) for organ transplants, with subsequent expansion into a broader portfolio of health innovations[201] ADIMUNE, INC. - Adimune, Inc. (formed Jan 2023) focuses on immune modulation therapeutic programs, with its proprietary Apoptotic DNA Immunotherapy™ (ADI™) designed to induce tolerance by mimicking natural body processes[202][209][210] - ADI-100, the lead product candidate, has completed preclinical studies demonstrating potential effectiveness in restoring durable tolerance for type-1 diabetes, psoriasis, and autoimmune CNS diseases, without impairing immune response to infection or cancer[203] - Clinical-grade drug substances have been successfully manufactured, and Adimune is preparing for clinical trials in Germany and an IND submission to the FDA for Stiff Person Syndrome (SPS) with Mayo Clinic, with human trials for SPS expected in 2025[204][206][207] - ADI™ technology, exclusively licensed from Loma Linda University, is a nucleic acid-based platform believed to selectively suppress only immune cells involved in attacking self/transplanted tissues, potentially allowing patients to live with transplanted organs with significantly reduced immune suppression[209][210][213] PEARSANTA, INC. - Pearsanta is pioneering the development of molecular tests based on mitochondrial DNA (mtDNA) for early cancer detection, leveraging the acquired Mitomic Technology platform, patents, and intellectual property[214][215][222] - Pearsanta has two product candidates in development: Mitomic® Prostate Test (MPT™) for prostate cancer diagnosis and Mitomic Endometriosis Test (MET™) for endometriosis detection, both designed as blood-based assays[216][229][230] - Pearsanta holds an exclusive worldwide sub-license for AditxtScore™ technology, which provides a personalized comprehensive profile of the immune system, intended to detect individual immune responses to various agents[217][218][221] - Pearsanta also acquired patents related to the detection and analysis of DNA adducts, intending to develop a platform for comprehensive assessment of DNA damage as early indicators of cancer risk[232][233] ADIVIR, INC. - Adivir, Inc. (formed April 2023) is a wholly-owned subsidiary focused on clinical and commercial development of innovative products for population health, including antiviral and antimicrobial products[235] - Aditxt had an Asset Purchase Agreement to acquire Cellvera's 50% ownership interest in G Response Aid FZE (which holds an exclusive worldwide license for Avigan® 200mg, excluding Japan, China, and Russia) for $24.5 million[236] - The consideration for the Cellvera acquisition included forgiveness of a $14.5 million loan to Cellvera Global and approximately $10 million in cash, plus future revenue sharing[236] - Due to Cellvera being subject to liquidation proceedings, Aditxt does not presently believe the proposed acquisition will be completed as proposed or at all[240] Our Team - The company has a team of experts with diverse scientific and commercial backgrounds, experienced in founding biotech companies, developing biopharmaceutical products, designing clinical trials, and managing companies[242] Going Concern - The company has a limited operating history, no significant revenues to date, and reported a net loss of $13,348,123 with a cash balance of $323,679 as of June 30, 2025[243] - Aditxt is over 90 days past due on a significant number of vendor obligations and requires substantial additional capital for operations and clinical studies[244] - These factors create substantial doubt about the company's ability to continue as a going concern beyond one year[244] Financial Results - The company has a limited operating history and has incurred substantial operating losses since inception, with a net loss of $13,348,123 as of June 30, 2025[245] - Aditxt expects to incur additional net expenses and significant operating losses for the foreseeable future, with future profitability being uncertain[245] Results of Operations Aditxt saw significant revenue and gross profit decline from decreased AditxtScore orders, incurring substantial operating losses Results of operations for the three months ended June 30, 2025 and 2024 | Metric | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | Change | | :--------------------------------- | :----------------------------- | :----------------------------- | :----- | | Revenue | $1,004 | $44,276 | $(43,272) | | Gross profit (loss) | $(1) | $21,142 | $(21,143) | | Loss from operations | $(6,152,395) | $(5,975,981) | $(176,414) | | General and administrative expenses | $5,039,036 | $4,419,545 | $619,491 | | Research and development expenses | $764,327 | $1,553,360 | $(789,033) | | Sales and marketing expenses | $349,031 | $24,218 | $324,813 | - The decrease in revenue and cost of goods sold was due to decreased AditxtScore orders from reduced COVID testing[246] - General and administrative expenses increased, primarily due to professional fees, while research and development expenses decreased significantly[248][249][250] Results of operations for the six months ended June 30, 2025 and 2024 | Metric | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change | | :--------------------------------- | :----------------------------- | :----------------------------- | :----- | | Revenue | $2,022 | $123,956 | $(121,934) | | Gross profit (loss) | $283 | $35,023 | $(34,740) | | Loss from operations | $(11,760,510) | $(17,511,627) | $5,751,117 | | General and administrative expenses | $9,387,310 | $7,783,293 | $1,604,017 | | Research and development expenses | $1,973,532 | $9,698,626 | $(7,725,094) | | Sales and marketing expenses | $399,951 | $64,731 | $335,220 | - The decrease in revenue and cost of goods sold was due to decreased AditxtScore orders from reduced COVID testing[251] - The decrease in total operating expenses for the six-month period was primarily due to a significant reduction in research and development spend, which included $6,712,663 in stock-based compensation in 2024[253][254] Liquidity and Capital Resources - The company has incurred substantial operating losses since inception, with an accumulated deficit of $181,061,686 and working capital of $(20,148,964) as of June 30, 2025[255] - Significant additional capital is required to fund operations and clinical trials, as current cash reserves are insufficient for the next 12 months, creating substantial doubt about the company's ability to continue as a going concern[257][259] - Future financing may involve selling common stock, preferred stock, convertible debt, credit facilities, or collaborative agreements, which could result in dilution to stockholders or restrictive covenants[257] Contractual Obligations | Obligation | Total 2025 (remaining) | 2026 | | :----------------- | :--------------------- | :--- | | Lease | $358,756 | $423,930 | | Total Lease Payments | $782,686 | | Critical Accounting Polices and Estimates - Critical accounting policies and estimates include those related to research and development expenses and stock-based compensation expense[261][265] - These policies involve significant judgment and assumptions, and actual results differing materially from estimates could significantly affect the company's reported financial condition and results of operations[261] Off-Balance Sheet Arrangements - The company did not have, and does not currently have, any off-balance sheet arrangements as defined by SEC rules and regulations[262] JOBS Act - As an "emerging growth company" under the JOBS Act, Aditxt has elected to use extended transition periods for complying with new or revised accounting standards[263][264] - The company intends to rely on exemptions such as not providing an auditor's attestation report on internal controls over financial reporting[266] - Aditxt will remain an "emerging growth company" until the earliest of reaching $1.07 billion in annual gross revenues, the fifth anniversary of its IPO (December 31, 2025), issuing over $1 billion in nonconvertible debt, or becoming a large accelerated filer[266] Recently Issued and Adopted Accounting Pronouncements - Management believes that recently issued ASUs either provide supplemental guidance, are technical corrections, are not applicable, or are not expected to have a significant impact on the company's financial statements[101][267] Recent Developments - Material recent developments are described in Note 13 – Subsequent Events[268] Item 3. Quantitative and Qualitative Disclosures About Market Risk Aditxt is not required to provide quantitative and qualitative disclosures about market risk as it qualifies as a "smaller reporting company" - Aditxt is exempt from providing quantitative and qualitative disclosures about market risk as it is a "smaller reporting company"[269] Item 4. Controls and Procedures Aditxt's CEO and CFO concluded disclosure controls were ineffective as of June 30, 2025, due to material weaknesses - As of June 30, 2025, the CEO and CFO concluded that disclosure controls and procedures were not effective[270] - Material weaknesses identified include inadequate documentation of accounting and financial reporting policies, insufficient expertise for technical and complex accounting issues, and insufficient procedures for accounts payable identification and cutoff[273] - These material weaknesses resulted in corrected financial statement misstatements, but no changes to previously released financial results[271] - No change occurred in internal control over financial reporting during the quarter ended June 30, 2025, that materially affected, or is reasonably likely to materially affect, internal control over financial reporting[272] PART II OTHER INFORMATION This section covers non-financial disclosures like legal proceedings, risk factors, equity sales, and exhibits Item 1. Legal Proceedings Aditxt may become involved in various lawsuits and legal proceedings, and adverse outcomes could materially harm the company's business - The company may become involved in various lawsuits and legal proceedings in the ordinary course of business[275] - Litigation is subject to inherent uncertainties, and an adverse result could materially harm the company's business[275] Item 1A. Risk Factors Aditxt faces significant risks including going concern doubts, overdue vendor obligations, potential foreclosure, and dilution - The company's financial situation creates substantial doubt about its ability to continue as a going concern, with no significant revenues to date and an accumulated deficit of $181,061,686 as of June 30, 2025[277] - Aditxt is over 90 days past due on approximately $5.7 million of its $9.7 million in accounts payable, and inability to repay or refinance substantial indebtedness could lead to default and foreclosure by secured creditors[278][281] - Delisting from Nasdaq could significantly adversely affect the value and liquidity of the company's securities and its ability to obtain financing[282] - A significant number of shares of common stock may be issued upon the exercise of outstanding options (59 shares), warrants (602,680 shares), and conversion of preferred stock, posing a risk of dilution and downward pressure on stock price[280] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds There were no unregistered sales of equity securities or use of proceeds to report during the period - No unregistered sales of equity securities or use of proceeds occurred during the period[284] Item 3. Defaults Upon Senior Securities There were no defaults upon senior securities to report during the period - No defaults upon senior securities occurred during the period[285] Item 4. Mine Safety Disclosures This item is not applicable to the company - This item is not applicable[286] Item 5. Other Information No Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted or terminated by directors or officers - No Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted or terminated by directors or officers during the six months ended June 30, 2025[287] Item 6. Exhibits This section lists the exhibits filed as part of the Form 10-Q, including certificates of amendment and certifications - The report includes various exhibits such as Certificate of Amendment to Certificate of Incorporation, Certifications of Principal Executive and Financial Officers, and Inline XBRL documents[288] Signatures The report is duly signed on behalf of Aditxt, Inc. by Amro Albanna, CEO, and Thomas J. Farley, CFO, on August 14, 2025 - The report was signed by Amro Albanna (CEO) and Thomas J. Farley (CFO) on August 14, 2025[294]